EcoDrugPlus

Nischarin

Ensembl ID : ENSPPRG00000022889
Gene Symbol: NISCH
3 Cross references
209 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSPPRG00000003356
Gene Symbol: NOS2
3 Cross references
163 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSPPRG00000014001
Gene Symbol: NOTCH3
3 Cross references
200 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSPPRG00000005244
Gene Symbol: NFKB1
4 Cross references
200 Possible Orthologues:

Nuclear Factor Kappa B Subunit 2

Ensembl ID : ENSPPRG00000024177
Gene Symbol: NFKB2
3 Cross references
124 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 2

Ensembl ID : ENSPPRG00000013614
Gene Symbol: NR1H2
3 Cross references
305 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSPPRG00000002008
Gene Symbol: NR1H3
4 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSPPRG00000004482
Gene Symbol: NR1H4
4 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSPPRG00000002713
Gene Symbol: NR3C1
4 Cross references
278 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSPPRG00000000130
Gene Symbol: NR3C2
4 Cross references
212 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSPPRG00000024296
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSPPRG00000005386
Gene Symbol: OPRD1
4 Cross references
252 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).